Tumor necrosis factor-related apoptosis-inducing ligand is a marker of kidney function and inflammation in heart and kidney transplant recipients

Transplantation Proceedings

Volumn 43, Issue 5, 2011, Pages 1877-1880

  Malyszko, J ^a,a   Przybylowski, P ^b   Koc Zorawska, E ^a   Mysliwiec, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CALCINEURIN INHIBITOR; CHOLESTEROL; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UREA; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CELL COUNT; CARDIAC GRAFT REJECTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; ERYTHROCYTE COUNT; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HEART EJECTION FRACTION; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY ALLOGRAFT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

BIOLOGICAL MARKERS; FEMALE; HEART TRANSPLANTATION; HUMANS; INFLAMMATION; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79959417852     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.03.035     Document Type: Article

References (25)

1. S.R. Wiley, K. Schooley, and P.J. Smolak Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673
2. Y. Michowitz, E. Goldstein, and A. Roth The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis J Am Coll Cardiol 45 2005 1018
3. M. Schoppet, N. Al-Fakhri, and F.E. Franke Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis J Clin Endocrinol Metab 89 2004 4104
4. M. Schoppet, A.M. Sattler, and J.R. Schaefer Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis Atherosclerosis 184 2006 446
5. J. Malyszko Endothelial dysfunction in chronic kidney disease Clin Chim Acta 411 2010 1411
6. S. Liabeuf, D.V. Barreto, and F.C. Barreto The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients Nephrol Dial Transplant 25 2010 2596
7. National Kidney Foundation K/DOQI Clinical Practice Guidelines for chronic kidney disease:evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1
8. Modification of Diet in Renal Disease Study Group Creatinine filtration, secretion and excretion during progressive renal disease Kidney Int 36 1989 S73
9. A.S. Levey, L.A. Stevens, and C.H. Schmid A new equation to estimate glomerular filtration rate Ann Intern Med 150 2009 604
10. F. Corallini, E. Rimondi, and P. Secchiero TRAIL and osteoprotegerin: a role in endothelial physiopathology? Front Biosci 13 2008 135
11. A. Collison, P.S. Foster, and J. Mattes The emerging role of TRAIL as key regulator of inflammatory responses Clin Exp Pharmacol Physiol 36 2009 1049
12. P. Secchiero, F. Corallini, and C. Ceconi Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction PLoS One 4 2009 e4442
13. N. Kayagaki, N. Yamaguchi, and M. Nakayama Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs J Exp Med 189 1999 1451
14. K. van der Putten, B. Braam, and K.E. Jie Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure Nat Clin Pract Nephrol 4 2008 47
15. A. Niessner, P.J. Hohensinner, and K. Rychli Prognostic value of apoptosis markers in advanced heart failure patients Eur Heart J 30 2009 789
16. D.C. Spierings, E.G. de Vries, and E. Vellenga Tissue distribution of the death ligand TRAIL and its receptors J Histochem Cytochem 52 2004 821
17. S.J. Zheng, P. Wang, and G. Tsabary Critical roles of TRAIL in hepatic cell death and hepatic inflammation J Clin Invest 113 2004 58
18. A. Krieg, T. Krieg, and M. Wenzel TRAIL-β and TRAIL-γ two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential Br J Cancer 88 2003 918
19. J.F. Navarro, and C. Mora-Fernandez The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications Cytokine Growth Factor Rev 17 2006 441
20. E.P. Mensah-Brown, E.N. Obineche, and S. Galadari Streptozotocin-induced diabetic nephropathy in rats: the role of inflammatory cytokines Cytokine 31 2005 180
21. J.H. Li, N.C. Kirkiles-Smith, and J.M. McNiff TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells J Immunol 171 2003 1526
22. L.B. Pritzker, M. Scatena, and C.M. Giachelli The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival Mol Biol Cell 15 2004 2834
23. G. Zauli, A. Pandolfi, and A. Gonelli Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells Circ Res 92 2003 732
24. P. Secchiero, F. Corallini, and M.G. di Iasio TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release Blood 105 2005 3413
25. S. Nomura, K. Ishii, and N. Inami Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentrations after stem cell transplantation Transpl Immunol 18 2007 115